FIC20210018I1 - Cenobamat eller ett farmaceutiskt salt därav - Google Patents
Cenobamat eller ett farmaceutiskt salt däravInfo
- Publication number
- FIC20210018I1 FIC20210018I1 FIC20210018C FIC20210018C FIC20210018I1 FI C20210018 I1 FIC20210018 I1 FI C20210018I1 FI C20210018 C FIC20210018 C FI C20210018C FI C20210018 C FIC20210018 C FI C20210018C FI C20210018 I1 FIC20210018 I1 FI C20210018I1
- Authority
- FI
- Finland
- Prior art keywords
- cenobamat
- därav
- salt
- farmaceutiskt
- eller ett
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FIC20210018I1 true FIC20210018I1 (fi) | 2021-06-14 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIC20210018C FIC20210018I1 (fi) | 2005-04-22 | 2021-06-14 | Cenobamat eller ett farmaceutiskt salt därav |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (enExample) |
| EP (1) | EP1879873B1 (enExample) |
| JP (1) | JP5035238B2 (enExample) |
| KR (1) | KR101286499B1 (enExample) |
| CN (1) | CN101228138B (enExample) |
| AR (1) | AR053065A1 (enExample) |
| AU (1) | AU2006237798B2 (enExample) |
| BE (1) | BE2021C524I2 (enExample) |
| BR (1) | BRPI0607529B8 (enExample) |
| CA (1) | CA2606258C (enExample) |
| DK (1) | DK1879873T3 (enExample) |
| ES (1) | ES2441765T3 (enExample) |
| FI (1) | FIC20210018I1 (enExample) |
| MX (1) | MX2007013197A (enExample) |
| MY (1) | MY148589A (enExample) |
| NL (1) | NL301106I2 (enExample) |
| PL (1) | PL1879873T3 (enExample) |
| PT (1) | PT1879873E (enExample) |
| RU (1) | RU2418792C2 (enExample) |
| TW (1) | TWI398249B (enExample) |
| WO (1) | WO2006112685A1 (enExample) |
| ZA (1) | ZA200709994B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US8815852B2 (en) * | 2007-05-14 | 2014-08-26 | Sk Biopharmaceuticals Co., Ltd. | Carbamoyloxy arylalkan arylpiperazine analgesics |
| BRPI0812740A2 (pt) | 2007-06-05 | 2016-07-19 | Nsab Af Neurosearch Sweden Ab | composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo. |
| KR101603487B1 (ko) * | 2008-06-05 | 2016-03-17 | 에스케이바이오팜 주식회사 | 3-치환된 프로판아민 화합물 |
| BRPI0924997B1 (pt) * | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| EP2800738B1 (en) * | 2012-01-06 | 2020-04-08 | Novartis AG | Heterocyclic compounds and methods for their use |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| EP3556363B1 (en) * | 2016-12-14 | 2024-03-06 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of pruritus |
| RU2761041C2 (ru) | 2016-12-14 | 2021-12-02 | ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Парентеральный жидкий препарат, включающий карбаматное соединение |
| MY198417A (en) * | 2016-12-14 | 2023-08-29 | Sk Biopharmaceuticals Co Ltd | Use of Carbamate Compound for Preventing, Alleviating, or Treating Tremors or Tremor Syndrome |
| EP3556365B1 (en) * | 2016-12-14 | 2025-07-02 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| WO2018111002A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 구강 붕해 정제 |
| EP3556366B1 (en) | 2016-12-14 | 2025-10-22 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| JP7355747B2 (ja) | 2017-11-14 | 2023-10-03 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
| EP3711761A4 (en) * | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO REDUCE OR TREAT DEVELOPMENTAL DISORDERS, INCLUDING FRAGILE X SYNDROME, ANGELMAN'S SYNDROME, OR RETT'S SYNDROME |
| KR102739580B1 (ko) * | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| ES2982316T3 (es) * | 2017-11-14 | 2024-10-15 | Sk Biopharmaceuticals Co Ltd | Uso de un compuesto de carbamato para prevenir, aliviar o tratar las crisis de ausencia o la epilepsia que muestra crisis de ausencia |
| EP3711757B1 (en) * | 2017-11-14 | 2025-05-07 | SK Biopharmaceuticals Co., Ltd. | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| EP3711756A4 (en) | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELAX, OR TREAT MYOTONIA |
| WO2020060252A1 (ko) | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| EP3854391B1 (en) * | 2018-09-21 | 2024-03-13 | SK Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| KR20210062029A (ko) * | 2018-10-19 | 2021-05-28 | 에스케이바이오팜 주식회사 | 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도 |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| AU2020389425A1 (en) * | 2019-11-22 | 2022-06-02 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
| KR20230048032A (ko) * | 2020-08-06 | 2023-04-10 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법 |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| WO1993004052A1 (en) * | 1991-08-22 | 1993-03-04 | Warner-Lambert Company | Amide tetrazole acat inhibitors |
| RU2298552C2 (ru) * | 2001-06-25 | 2007-05-10 | СК Корпорейшн | Карбаматы 2-гетероциклил-1,2-этандиолов |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20210018I1 (fi) | Cenobamat eller ett farmaceutiskt salt därav | |
| NO2018037I1 (no) | Simeprevir, eller salt derav, innbefattende natrium-simeprevir | |
| DK2206707T3 (da) | Azolcarboxamidforbindelse eller salt deraf | |
| CY2013047I1 (el) | Ενωσεις διαρυλυδαντοϊνης | |
| DK1893477T3 (da) | Skib | |
| NO2018027I2 (no) | [18F]FACBC eller fluciklovin | |
| ATE408603T1 (de) | Pyrazolylcarboxanilide | |
| DK1855941T3 (da) | Fremdrivningsindretning | |
| EP1775630A4 (en) | BAG | |
| FI20055649L (fi) | Paikanmääritystekniikoita | |
| DK1931713T3 (da) | Aryl-/alkylravsyreanhydridhyaluronderivater | |
| DK2042480T3 (da) | Aminoindan-derivat eller salt deraf | |
| ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
| EP1914266A4 (en) | PREPREG | |
| NO20082650L (no) | Benzenderivat eller salt derav | |
| FI20080436L (fi) | Terä | |
| PL380808A1 (pl) | Ostrogorynna prowadząca struga mieczowego | |
| DE502006007704D1 (de) | Fördereinheit | |
| ITMI20052367A1 (it) | Cristallizzatore | |
| DE502006006792D1 (de) | Fördereinheit | |
| DE502006007983D1 (de) | Rettungsweste | |
| AT501968A3 (de) | Mitführhilfe | |
| DE602005020522D1 (de) | Dreidimensionaler lochfilm | |
| ITRM20050612A1 (it) | Cristallizzatore | |
| SE0501388L (sv) | Fjäder |